Developmental Activity of the Renin-Angiotensin System during the "Critical Period" Modulates Later L-NAME-Induced Hypertension and Renal Injury
Open Access
- 1 January 2007
- journal article
- Published by Japanese Society of Hypertension in Hypertension Research
- Vol. 30 (1) , 63-75
- https://doi.org/10.1291/hypres.30.63
Abstract
The incidence of hypertension and hypertensive renal disease is increasing worldwide, and new strategies to prevent these diseases need to be investigated. The aims of this study were 1) to examine if transient exposure to an angiotensin receptor blocker (ARB) during an early period in hypertension development confers protection against subsequent worsening of hypertension and renal injury induced by the NO synthase inhibitor NG-nitro-L-arginine methyl ester (L-NAME), and 2) conversely, to examine the effects of transient exposure to angiotensin II (Ang II) during the same period. First, spontaneously hypertensive rats (SHR) were treated transiently from age 3 to 10 weeks with an ARB (candesartan cilexetil), a calcium channel antagonist or a vasodilator, then taken off treatment for 2 months. Administration of L-NAME at age 18 weeks caused severe hypertension and renal injury. However, the rats that had been exposed to the ARB not only had a lower blood pressure, but also failed to show signs of renal injury or increase of oxidative stress. Furthermore, the elevation of components of the renin-angiotensin-aldosterone system was also suppressed in these rats. In the second study, Wistar-Kyoto rats (WKY) and SHR were exposed to Ang II from age 4 to 8 weeks. The follow-up showed that the blood pressures in the WKY remained elevated compared to controls, while the SHR had heightened increases in blood pressure, renal renin mRNA, and urinary 8-hyroxydeoxyguanosine after L-NAME administration. Together, these experiments demonstrate that transient treatment of rats during an early phase in the development of hypertension with an ARB suppresses the renin-angiotensin-aldosterone system and confers long-term protection against subsequent L-NAME–induced renal injury and increases in renal oxidative stress. Conversely, developmental exposure to Ang II during this “critical” period had the opposite effect, predisposing rats to higher blood pressure, renal injury, and oxidative stress after L-NAME administration.Keywords
This publication has 21 references indexed in Scilit:
- Feasibility of Treating Prehypertension with an Angiotensin-Receptor BlockerNew England Journal of Medicine, 2006
- Temporary Angiotensin II Blockade at the Prediabetic Stage Attenuates the Development of Renal Injury in Type 2 Diabetic RatsJournal of the American Society of Nephrology, 2005
- Calcium Channel Blockades Exhibit Anti-Inflammatory and Antioxidative Effects by Augmentation of Endothelial Nitric Oxide Synthase and the Inhibition of Angiotensin Converting Enzyme in the NG-Nitro-L-Arginine Methyl Ester-Induced Hypertensive Rat Aorta: Vasoprotective Effects beyond the Blood Pressure-Lowering Effects of Amlodipine and ManidipineHypertension Research, 2005
- Effective treatments for insulin resistance: trim the fat and douse the fireTrends in Endocrinology & Metabolism, 2004
- Superoxide: a key player in hypertensionThe FASEB Journal, 2003
- Simple Procedure for Specific Assay of Lipid Hydroperoxides in Serum or PlasmaPublished by Springer Nature ,1998
- Prevention of genetic hypertension by early treatment of spontaneously hypertensive rats with the angiotensin converting enzyme inhibitor captopril.Hypertension, 1993
- Brief angiotensin converting enzyme inhibitor treatment in young spontaneously hypertensive rats reduces blood pressure long-term.Hypertension, 1990
- Enalapril can prevent vascular amplifier development in spontaneously hypertensive rats.Hypertension, 1990
- Global burden of hypertension: analysis of worldwide dataPublished by Elsevier